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Abstract
Corticotropin-releasing factor receptor CRF1 has been implicated in the neurobiological
mechanisms of anxiety and depression. The amygdala plays an important role in affective states and
disorders such as anxiety and depression. The amygdala is also emerging as a neural substrate of
pain affect. However, the involvement of the amygdala in the interaction of pain and anxiety remains
to be determined. This study tested the hypothesis that CRF1 receptors in the amygdala are
critically involved in pain-related anxiety. Anxiety-like behavior was determined in adult male rats
using the elevated plus maze (EPM) test. The open-arm preference (ratio of open arm entries to
the total number of entries) was measured. Nocifensive behavior was assessed by measuring
hindlimb withdrawal thresholds for noxious mechanical stimulation of the knee. Measurements
were made in normal rats and in rats with arthritis induced in one knee by intraarticular injections
of kaolin/carrageenan. A selective CRF1 receptor antagonist (NBI27914) or vehicle was
administered systemically (i.p.) or into the central nucleus of the amygdala (CeA, by microdialysis).
The arthritis group showed a decreased preference for the open arms in the EPM and decreased
hindlimb withdrawal thresholds. Systemic or intraamygdalar (into the CeA) administration of
NBI27914, but not vehicle, inhibited anxiety-like behavior and nocifensive pain responses, nearly
reversing the arthritis pain-related changes. This study shows for the first time that CRF1 receptors
in the amygdala contribute critically to pain-related anxiety-like behavior and nocifensive responses
in a model of arthritic pain. The results are a direct demonstration that the clinically well-
documented relationship between pain and anxiety involves the amygdala.
Background
Pain, including arthritis pain, has a negative affective
component and is closely related to anxiety and depres-
sion [1-3]. The neural pathways and mechanisms
involved in pain-related anxiety remain to be determined,
but the amygdala is known to play a key role in emo-
tional-affective behavior and anxiety disorders [4-6].
Importantly, the amygdala is emerging as an important
element of the brain network involved in the emotional-
affective component of pain [7-11]. The amygdala is also
believed to be a key substrate of the reciprocal relation-
ship between pain and affective states and disorders such
as anxiety [3,10,12,13].
Our previous studies demonstrated central sensitization
[14-19] and synaptic plasticity [14,20-23] in the central
nucleus of the amygdala (CeA) in the kaolin/carrageenan-
induced arthritis pain model. The CeA integrates affect-
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related information from the fear-anxiety circuitry in the
lateral-basolateral amygdala with purely nociceptive
inputs from the spino-parabrachio-amygdaloid pain
pathway [7,9,10]. Pain-related synaptic plasticity in the
CeA has also been confirmed in a model of chronic neu-
ropathic pain [24]. It has become clear now that reversal
of pain-related plasticity by pharmacologic deactivation
of the CeA decreases nocifensive and affective pain
responses in animal models of arthritic pain [14,25], vis-
ceral pain [26] and neuropathic pain [11] and in the pro-
longed phase of the formalin test [27].
The present study focused on the role of corticotropin-
releasing factor receptor 1 (CRF1) in the CeA in pain-
related anxiety. The CeA is a major site of extrahypotha-
lamic expression of CRF and a key element of the extrahy-
pothalamic circuits through which CRF contributes to
anxiety-like behavior and affective disorders [28-32].
CRF1 receptors have emerged as drug targets for depres-
sion and anxiety disorders in preclinical studies [29-
31,33-36]. A CRF1 receptor antagonist has been used suc-
cessfully in humans to reduce depression and anxiety
scores [37,38]. Finally, the presence of CRF-containing
neurons in the parabrachial area [39] links the CRF system
in the amygdala to the spino-parabrachio-amygdaloid
pain pathway and implicates CRF in the transmission of
nociceptive information to the amygdala.
Findings
The behavioral and pharmacological studies reported
here tested the hypothesis that CRF1 receptors in the amy-
gdala (CeA) are critically involved in pain-related anxiety-
like behavior. Adult male Sprague-Dawley rats (250–350
g) were used. All experimental procedures were approved
by the Institutional Animal Care and Use Committee
(IACUC) at the University of Texas Medical Branch
(UTMB) and conform to the guidelines of the Interna-
tional Association for the Study of Pain (IASP) and of the
National Institutes of Health (NIH).
Anxiety-like behavior was determined using the elevated
plus maze (EPM) test [40] (Figure 1). The open-arm pref-
erence (ratio of open arm entries to the total number of
entries expressed as %) was measured for 45 min using a
computerized recording and analysis system (Multi-Var-
imex v1.00; Columbus Instruments, OH, USA). Each rat
was tested once on day 1 (normal baseline) and again on
day 2 5–6 hours after intraarticular injection of sterile
saline (control group) or kaolin and carrageenan (arthritis
group) as previously described in detail [14,25,41,42]. In
the control group (n = 5 rats), the percentage of open-arm
choices (preference) was not significantly different
between day 1 (normal baseline) and day 2 (intraarticular
saline; P > 0.05, paired t-test; Fig. 1A). These data show
that repeating the EPM test on day 2 does not per se alter
Increased anxiety-like behavior in the arthritis pain model (A)  is decreased by a CRF1 receptor antagonist (B) Figure 1
Increased anxiety-like behavior in the arthritis pain 
model (A) is decreased by a CRF1 receptor antagonist 
(B). Anxiety-like behavior of adult male rats was determined by 
measuring the open-arm preference (ratio of open arm entries to 
the total number of entries expressed as %) in the elevated plus 
maze (EPM) test. (A) Open-arm choice did not change in control 
rats (n = 5) after intraarticular saline injections on day 2 compared 
to normal baseline on day 1. Rats with arthritis (n = 7; 5–6 h 
postinjection of kaolin/carrageenan into the knee on day 2) 
showed a significantly decreased open-arm preference compared 
to normal baseline on day 1 (P < 0.05, paired t-test), suggesting 
increased anxiety-like behavior. (B) A CRF1 receptor antagonist 
(NBI27914) administered systemically (5 mg/kg i.p.; n = 5) or into 
the CeA by microdialysis (100 µM, concentration in microdialysis 
fiber, 2 µl/min; n = 5) increased the open-arm preference signifi-
cantly (P < 0.05, compared to vehicle groups; Newman-Keuls Mul-
tiple Comparison Test). Systemic (i.p.) application of saline (n = 5) 
or intra-amygdalar administration of ACSF (n = 5) as vehicle con-
trols had no significant effect on open-arm choices compared to 
arthritic rats without any interventions (n = 6; P > 0.05; Newman-
Keuls Multiple Comparison Test). Bar histograms show the mean 
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baseline behavior. In the arthritis group (n = 7 rats), the
open-arm preference decreased significantly (P < 0.05,
paired t-test) 5–6 hours after arthritis induction (day 2)
compared to normal baseline behavior (day 1), suggest-
ing increased anxiety-like behavior (Fig. 1A).
Next we determined the effects of a selective CRF1 recep-
tor antagonist (5-chloro-4-(N-(cyclopropyl)methyl-N-
propylamino)-2-methyl-6-(2,4,6-trichlorophenyl)
amino-pyridine, NBI 27914 [43]; purchased from Tocris
Bioscience, Ellisville, MO). NBI27014 was administered
either systemically (intraperitoneally, i.p.) or locally into
the amygdala (CeA) by microdialysis in rats with arthritis
(Fig. 1B). For drug application by microdialysis a guide
cannula was implanted stereotaxically on the dorsal mar-
gin of the CeA as previously described in detail using the
following coordinates [14,25]: 1.8–2.0 mm caudal to
bregma, 4.0 mm lateral to midline, depth 7.0 mm. On the
day of the experiment a microdialysis probe (CMA/Micro-
dialysis 11; membrane diameter: 250 µm, membrane
length: 2 mm) was inserted into the CeA through the
guide cannula so that the probe protruded by 2 mm. The
probe was connected to a Harvard infusion pump and
perfused with ACSF (2 µl/min) for at least 1 h to establish
equilibrium in the tissue.
Anxiety-like behavior was measured in 5 groups of rats to
determine the role of CRF1 receptors: arthritic rats with-
out any additional intervention; arthritic rats that received
systemic administration of vehicle (saline); arthritic rats
with systemic administration of NBI27014 (5 mg/kg,
i.p.); arthritic rats with vehicle (ACSF) administration into
the CeA; and arthritic rats with intra-CeA administration
of NBI27014 (100 µM; concentration in microdialysis
probe which is 100-fold that predicted to be needed based
on data from our previous studies [15]). The open-arm
preferences of arthritic rats without any interventions (n =
6) and of arthritis rats with systemic saline (n = 5) or intra-
amygdala ACSF (n = 5) were not significantly different (P
> 0.05, Newman-Keuls Multiple Comparison Test; Graph-
Pad Prism software 3.0; Fig. 1B). Systemic application of
NBI27914 30 min before the EPM test in increased the
open-arm preference significantly (n = 5; P < 0.05, com-
pared to saline group; Newman-Keuls Multiple Compari-
son Test). Administration of NBI27914 into the CeA for
30 min also increased the open-arm preference signifi-
cantly (n = 5; P < 0.05, compared to ACSF control group;
Newman-Keuls Multiple Comparison Test). The effects of
systemic and intra-CeA administration of NBI27914 were
not significantly different (P > 0.05; Newman-Keuls Mul-
tiple Comparison Test), suggesting that CRF1 receptors in
the amygdala (CeA) account for the anxiolytic effect of
CRF1 receptor antagonists.
We also determined the effects of a CRF1 antagonist on
nocifensive responses (Fig. 2). Thresholds of hindlimb
withdrawal reflexes evoked by mechanical stimulation of
the knee joint were measured as previously described in
detail [41,42]. Animals were paced in a custom-designed
recording chamber that ensured stable and reproducible
stimulations of the knee. Mechanical stimuli (compres-
sion) of continuously increasing intensity were applied to
the knee joint using a calibrated forceps with a force trans-
ducer whose output was digitized and recorded on a com-
puter. Measurements were made before (normal baseline)
and 5–6 hours after arthritis induction. Arthritic rats
received either systemic (n = 5; Fig. 2A) or intra-CeA (n =
7; Fig. 2B) administrations of NBI27914. Both groups of
arthritic animals had significantly decreased hindlimb
withdrawal thresholds indicating mechanical hypersensi-
tivity (P < 0.001; repeated measures ANOVA followed by
Newman-Keuls Multiple Comparison Test). Systemic
administration of NBI27914 (5 mg/kg; n = 5) significantly
increased the hindlimb withdrawal thresholds at 45 min
(P < 0.05) and 60 min (P < 0.01) after i.p. injection
(repeated measures ANOVA followed by Dunnett's post-
hoc test; Fig. 2A). Intra-CeA administration of NBI27914
(100 µM; concentration in microdialysis fiber; Fig. 2B)
also increased the hindlimb withdrawal thresholds signif-
icantly (P < 0.05; repeated measures ANOVA followed by
Newman-Keuls Multiple Comparison Test).
Conclusion
In summary, this study showed that systemic or intra-
amygdalar administration of a CRF1 receptor antagonist
decreased anxiety-like behavior and nocifensive reflex
responses in a model of arthritis pain, suggesting a key
role of CRF1 receptors in the amygdala (CeA) in the mod-
ulation of pain-related anxiety. The novelty of this study is
that it directly links the amygdala, through CRF1 receptors
in the CeA, to pain-related anxiety, which is clinically
well-documented but mechanistically not well under-
stood.
Although the amygdala is known to play a key role in anx-
iety-like behavior through mechanisms that appear to
involve CRF [28-32,44], its contribution to pain-related
anxiety remains to be determined. Recent biochemical
[45-47] and behavioral [48-51] studies point to the amy-
gdala as an important site for the pain-modulatory effects
of CRF. Increased expression of CRF1 receptor mRNA was
detected in the amygdala in a model of somato-visceral
pain induced by intra-peritoneal acetic acid [46]. CRF
mRNA increased in the CeA in models of colitis pain [45]
and chronic neuropathic pain [47]. Intracerebroventricu-
lar or intra-CeA administration of a broad-spectrum CRF
receptor antagonist (alpha-hCRF9-41) had antinocicep-
tive effects on hyperalgesic behavior associated with opi-
ate withdrawal [50]. Systemic administration of a CRF1Molecular Pain 2007, 3:13 http://www.molecularpain.com/content/3/1/13
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receptor antagonist nearly reversed colon hypersensitivity
(visceromotor response) induced by stereotaxic delivery
of corticosterone to the CeA [49]. On the other hand,
intra-CeA administration of a non-selective CRF receptor
antagonist (alpha-hCRF9-41) produced hyperalgesic
behavior (decreased mechanical and thermal withdrawal
thresholds) and attenuated the antinociceptive effects of
CRF administered into the CeA in normal animals [48].
The reason for these conflicting findings is unclear at this
time. Our recent electrophysiological data show that
administration of a CRF1 receptor antagonist (NBI27914)
into the CeA clearly inhibits the sensitization of CeA neu-
rons in the arthritis pain model. Taken together with the
present study, these findings suggest that CRF1 receptors
critically contribute to pain-related sensitization that
results in increased pain responses and anxiety-like behav-
ior.
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